HALO

Halozyme Therapeutics, Inc.

Healthcare›Biotechnology|NASDAQ Global Select|US

Price

$64.49

Market Cap

$7.61B

Beta

1.03

P/E

25.5

Div Yield

—

Sector Median P/E

22.6

Key Metrics

Revenue Growth (YoY)+37.55%

EPS Growth (YoY)-27.41%

Revenue CAGR 3Y+28.38%

P/E Ratio25.5

PEG Ratio—

FCF Yield+8.47%

Debt / Equity0.00

Interest Coverage45.0x

No credit card required

Already have an account? Sign in to view the full analysis for HALO.